IMV, Inc.
(Toronto Stock Exchange : IMV)

( )
IMV PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.61%185.710.0%$901.88m
AMGNAmgen, Inc. -0.28%245.551.5%$590.34m
NVAXNovavax, Inc. -2.07%59.0275.7%$452.24m
VRTXVertex Pharmaceuticals, Inc. 1.03%291.001.9%$424.20m
GILDGilead Sciences, Inc. 0.34%61.301.0%$373.56m
REGNRegeneron Pharmaceuticals, Inc. -0.02%613.512.6%$344.39m
SNSSSunesis Pharmaceuticals, Inc. 0.00%3.870.7%$270.53m
ILMNIllumina, Inc. 0.64%225.193.3%$243.06m
BIIBBiogen, Inc. 0.83%220.001.8%$202.89m
GOVXGeoVax Labs, Inc. 2.80%3.310.0%$164.90m
BNTXBioNTech SE -6.67%170.900.0%$143.09m
CRSPCRISPR Therapeutics AG -0.82%80.730.6%$131.68m
MRTXMirati Therapeutics, Inc. 8.60%94.001.6%$101.56m
PLRXPliant Therapeutics, Inc. 3.12%19.500.0%$98.38m
RYTMRhythm Pharmaceuticals, Inc. 5.63%21.380.0%$96.44m

Company Profile

IMV, Inc. is a clinical-stage biopharmaceutical company, which engaged in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The firm leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.